PRODUCT
首頁
產品資訊
PRODUCT
首頁
產品資訊
產品特點
| 編號 | 名稱 | 描述 | 純度 |
| HB1804 | Escitalopram oxalate | Selective serotonin reuptake inhibitor (SSRI) | >99% |
| HB0278 | ET-18-OCH3 | Selective PLC inhibitor | >95% |
| HB3894 | Eupatilin | Selective 5-lipoxygenase (5-LOX) inhibitor | >98% |
| HB0280 | Evans blue | Potent AMPA / kainate receptor antagonist. Vesicular L-glutamate uptake inhibitor. | |
| HB0283 | Fasudil hydrochloride | ROCK and cyclic nucleotide-dependent protein kinase inhibitor | >98% |
| HB1222 | Felodipine | Selective L-type VOCC blocker | >98% |
| HB0286 | Fenobam | Potent, selective, non-competitive mGlu5antagonist | >99% |
| HB0287 | Fenvalerate | Calcineurin inhibitor | >98% |
| HB0288 | FH 535 | Wnt/β-catenin inhibitor and PPARγ/δ antagonist. | >99% |
| HB1386 | FK 228 | Potent, selective HDAC1 / HDAC2 inhibitor | >98% |
| HB0289 | FK 506 | Potent calcineurin phosphatase 2B inhibitor | >99% |
| HB0915 | Flumazenil | GABAA receptor antagonist | >99% |
| HB1600 | Fluoxetine hydrochloride | Selective 5-HT uptake inhibitor | >99% |
| HB1932 | Flupenthixol dihydrochloride | Dopamine receptor antagonist | >99% |
| HB3049 | Flurbiprofen | Cyclooxygenase inhibitor. Regulates prostate stem cell antigen. | >99% |
| HB2138 | Fluvoxamine maleate | Selective serotonin reuptake inhibitor and σ1 receptor agonist | >98% |
| HB0293 | Fostriecin sodium salt | Potent protein phosphatase inhibitor | >98% |
| HB1249 | FPA 124 | Akt inhibitor | |
| HB3901 | Fumagillin | Methionine aminopeptidase-2 inhibitor | >98% |
| HB3071 | Fumitremorgin C | BCRP-mediated multidrug resistance inhibitor | >98% |
| HB3904 | Funalenone | Matrix metalloproteinase-1 (MMP-1) inhibitor | >95% |
| HB3905 | Fuscin | CCR5 receptor antagonist | >95% |
| HB0882 | GABA | Endogenous inhibitory neurotransmitter | |
| HB0857 | Gabapentin | Glutamate release inhibitor / VSCC modulator | >99% |
| HB3313 | GANT 58 | GLI1 antagonist. Hedgehog signaling inhibitor. | >99% |
| HB3394 | GANT61 | GLI antagonist. Also Hedgehog (Hh) signaling inhibitor. | >98% |
| HB1812 | GBR 12909 dihydrochloride | Potent, competitive dopamine uptake inhibitor | >98% |
| HB3311 | Geldanamycin | Selective Hsp90 inhibitor. Breast cancer stem cell inhibitor. | >98% |
| HB0299 | Glycine | Inhibitory neurotransmitter, NMDA receptor co-agonist | |
| HB2292 | Glycyl-H 1152 dihydrochloride | Potent, selective ROCK inhibitor | >99% |
| HB0302 | Go 6976 | Potent, selective PKC inhibitor | >98% |
| HB0303 | Go 6983 | Broad spectrum PKC inhibitor | >98% |
| HB0304 | Gossypol | Dehydrogenase enzyme inhibitor | >90% |
| HB0305 | Gramine | 5-HT2A receptor antagonist | >99% |
| HB2838 | Granisetron hydrochloride | 5-HT3 antagonist | >99% |
| HB2290 | GSK 429286 | Selective ROCK inhibitor | >97% |
| HB1405 | GSK J1 | Potent, selective histone demethylase KDM6 subfamily inhibitor | >99% |
| HB1407 | GSK J4 | JMJD3 / UTX Histone demethylase inhibitor | >99% |
| HB0311 | GYKI 52466 hydrochloride | Selective, non-competitive AMPA receptor antagonist | >99% |
| HB0318 | H-8 | PKA / PKG inhibitor | >98% |
| HB0314 | H 89 dihydrochloride | Potent, non-selective kinase inhibitor | >99% |
| HB2293 | HA 1100 hydrochloride | Selective, reversible, cell-permeable ROCK inhibitor | >99% |
| HB1665 | Harmane | Imidazoline I1 ligand. Potent MAO-A and MAO-B inhibitor. | >99% |
| HB3925 | Harzianopyridone | Specific mitochondrial complex II inhibitor | >95% |
| HB1158 | HC 030031 | Selective TRPA1 channel blocker | >99% |
| HB1191 | HC 067047 | Potent, selective TRPV4 channel antagonist | >98% |
| HB3927 | Helenalin | NF-κB inhibitor | >97% |
| HB3928 | Heliquinomycin | DNA helicase inhibitor | >80% |
| HB1325 | Herbimycin A | Src family kinase inhibitor | >99% |
| HB1428 | 1,2,3,4,5,6-Hexabromocyclohexane | Potent, selective JAK2 inhibitor | |
| HB0067 | 1-O-Hexadecyl-2-O-acetyl-sn-glycerol | PKC inhibitor | >98% |
| HB4660 | Homoharringtonine | Protein synthesis inhibitor | >98% |
| HB0060 | 12(S)-HPETE | CaM kinase II inhibitor | >98% |
| HB0001 | (-)-Huperzine A | AChE inhibitor / NMDA receptor antagonist | >97% |
| HB4640 | (R)-3-Hydroxybutyric acid | Endogenous HDAC1, HDAC3 and HDAC4 inhibitor | >98% |
| HB4641 | (S)-3-Hydroxybutyric acid | Endogenous HDAC1, HDAC3 and HDAC4 inhibitor | >98% |
| HB6040 | 4-Hydroxytamoxifen ≥70% Z isomer (remainder primarily E-isomer) | Synthetic estrogen receptor ligand. Widely used in genome engineering (e.g. CreER/ CRISPR-Cas9). | >98% |
| HB3701 | (R,R)-Hymeglusin | Specific and irreversible HMG-CoA synthase inhibitor | >95% |
| HB1264 | 10Z-Hymenialdisine | Pan kinase inhibitor. Potently inhibits MEK1, Cdk1, Cdk2, Cdk3 and Cdk5 and GSK-3β. | >97% |
| HB1053 | Iberiotoxin | Potent, reversible, selective KCa channel inhibitor | |
| HB1446 | I-BET 151 hydrochloride | BET bromodomain inhibitor | >98% |
| HB3000 | IBMX | Non-selective, competitive cAMP and cGMP PDE inhibitor. Facilitates neural progenitor cell differentiation. | >99% |
| HB4204 | Ibrutinib | Potent, selective Bruton’s tyrosine kinase (BTK) inhibitor | >98% |
| HB1447 | I-CBP 112 | CBP/p300 Bromodomain inhibitor | >98% |
| HB0331 | ICG 001 | Selective, competitive inhibitor of β-catenin/CBP interaction | >98% |
| HB2501 | ICI 182,780 (Fulvestrant) | Estrogen receptor (ER) antagonist and high affinity GPER agonist | >99% |
| HB0338 | IEM-1460 | Competitive, selective, GluA2 (GluR2)-lacking AMPA receptor blocker | |
| HB0339 | Ifenprodil | Non-competitive GluN2B subunit selective NMDAR allosteric inhibitor | >99% |
| HB4639 | IHR-NAc | Sonic hedgehog (Shh) signaling pathway inhibitor | >98% |
| HB0341 | Indole-3-acetamide | Competitive Tryptophan 2-monooxygenase oxidase inhibitor | >98% |
| HB4422 | Indomethacin | Cyclooxygenase inhibitor | >99% |
| HB2204 | INDY | Dyrk1A/B inhibitor. Impairs NSCs self-renewal. | >98% |
| HB1193 | 5’-Iodoresiniferatoxin | Potent TRPV1 channel antagonist | >98% |
| HB1409 | IOX 1 | JMJD histone demethylase inhibitor | >99% |
| HB3942 | Iromycin A | NOS inhibitor | >98% |
| HB3707 | 1,5-Isoquinolinediol | PARP-1 inhibitor. Potent iNOS inhibitor | >98% |
| HB1223 | Isradipine | L-type voltage gated calcium channel blocker | >99% |
| HB3446 | ITD 1 | Selective TGF-β signaling inhibitor. Induces cardiomyocyte differentiation in ESCs. | >98% |
| HB1284 | Ivachtin | Potent caspase-3 inhibitor | >99% |
| HB3163 | IWP 12 | Potent PORCN inhibitor | >98% |
| HB0344 | IWP 2 | Potent Wnt pathway inhibitor and PORCN inhibitor. Suppresses R1 ESC self-renewal. | >98% |
| HB3066 | IWP 4 | Potent Wnt/β-catenin signaling inhibitor. Induces cardiomyocyte differentiation of hESCs and iPSCs. | >98% |
| HB3134 | IWP L6 | Potent PORCN inhibitor. Supresses R1 ESCs self renewal | >98% |
| HB3083 | Jervine | Hedgehog signaling inhibitor. Directly binds to Smo. | >98% |
| HB6127 | JF-NP-26 (Caged-Raseglurant) | Novel, inactive photocaged derivative of raseglurant which can be uncaged with violet light. Shows light-dependent analgesic activity in vivo. | >98% |
| HB1410 | JIB 04 | Jumonji histone demethylase inhibitor | >99% |
| HB3179 | JK 184 | Downstream Hedgehog signaling pathway inhibitor. Alcohol dehydrogenase 7 inhibitor. | >99% |
| HB1596 | JNJ 10191584 maleate | Potent, selective H4 receptor silent antagonist | >99% |
| HB0348 | JNJ 16259685 | Potent, selective, non-competitive mGlu1antagonist | >98% |
| HB1448 | (+)-JQ1 | Potent, selective, competitive BET bromodomain inhibitor | >98% |
| HB1298 | JX 401 | Potent, reversible p38α MAPK inhibitor | >98% |
| HB0351 | K-252a | Non-selective protein kinase inhibitor | >97% |
| HB0352 | K-252b | Potent PKC and casein kinase II inhibitor | >98% |
| HB0353 | K252c | PKC inhibitor | >99% |
| HB1133 | KB-R7943 mesylate | Selective, reverse mode Na+/ Ca2+ exchange inhibitor | >99% |
| HB1019 | KC 12291 hydrochloride | Atypical voltage-gated sodium channel blocker | >97% |
| HB3950 | Kendomycin | Potent endothelin receptor antagonist | >98% |
| HB1266 | Kenpaullone | Potent CDK inhibitor. Also GSK-3 inhibitor. Generates iPSCs. | >98% |
| HB1641 | Ketanserin tartrate | Selective 5-HT2 receptor antagonist | >97% |
| HB0359 | KN-62 | Selective CaM kinase II inhibitor. P2X7 receptor antagonist. | >98% |
| HB0358 | KN 92 | Reduces Cav1.2 and Cav1.3 channel currents. Inactive analog of KN 93. | >98% |
| HB0360 | KN-93 phosphate (water soluble) | Potent CaM kinase II inhibitor | >98% |
| HB0361 | KT 5720 | Potent, selective PKA inhibitor | >98% |
| HB1316 | KT 5823 | Potent, selective PKG inhibitor | >98% |
| HB2250 | KU 0063794 | Potent, selective mTOR inhibitor | >97% |
| HB3465 | KY 02111 | Wnt signaling inhibitor. Promotes differentiation of hESCs and iPSCs into cardiomyocytes. | >99% |
| HB0362 | Kynurenic acid | Endogenous ionotropic glutamate / nicotinic antagonist. | >98% |
| HB0363 | Kynurenic acid sodium salt | Endogenous ionotropic glutamate / nicotinic antagonist. Sodium salt | >98% |
| HB0368 | Lamotrigine | Na2+ / K+ / Ca2+ channel inhibitor. Anticonvulsant. | >99% |
| HB3694 | (3S,6R)-Lateritin | Acyl-CoA cholesterol acyltransferase (ACAT) inhibitor | >97% |
| HB0375 | Latrunculin A | Actin polymerization inhibitor | >96% |
| HB0376 | Lavendustin C | Potent EGFR tyrosine kinase inhibitor | >98% |
| HB1868 | LE 300 | Potent, selective D1 receptor antagonist | >98% |
| HB1429 | Lestaurtinib | Potent, non-selective tyrosine kinase inhibitor | >99% |
| HB4637 | Linagliptin | Highly potent, selective, competitive dipeptidyl-peptidase 4 inhibitor | >98% |
| HB1082 | Linopirdine dihydrochloride | Kv7 channel blocker | >99% |
| HB1376 | Lomeguatrib | Potent MGMT inhibitor | >98% |
| HB0993 | Lonidamine | Mitochondrial hexokinase inhibitor | >98% |
| HB2266 | LY 294002 hydrochloride | PI3-K inhibitor. Suppresses mESC proliferation. | >99% |
| HB1751 | LY 310762 hydrochloride | 5-HT1D-preferring receptor antagonist | >98% |
| B0398 | LY367385 | Potent, highly selective mGlu1a antagonist | >98% |
| HB2267 | 3-Methyladenine | PI-3K inhibitor | >99% |
| HB3963 | Macrosphelide A | Cell-cell adhesion inhibitor | >95% |
| HB3968 | Manumycin B | Rasfarnesyltransferase inhibitor | >98% |
| HB1083 | Margatoxin | Potent, non-selective Kv1.3 channel blocker | |
| HB1390 | MC 1568 | Selective class IIa HDAC inhibitor | >96% |
| HB4636 | MCC950 sodium salt | Potent, selective NLRP3 inflammasome inhibitor | >98% |
| HB0037 | (RS)-MCPG | Non-selective group I and II mGluR antagonist | >98% |
| HB0056 | (S)-MCPG | Non-selective group I/II mGluR antagonist | >99% |
| HB6112 | (S)-MCPG sodium salt | Non-selective group I and II mGluR antagonist. Water soluble sodium salt. | >99% |
| HB0038 | (R,S)-MCPG sodium salt | Water soluble, non-selective group I and II mGluR antagonist | >98% |
| HB1602 | MDCPG | Selective mGlu8 receptor antagonist | |
| HB1780 | MDL 100907 | Potent and selective 5-HT2A receptor antagonist | >98% |
| HB1874 | Melanocyte-stimulating hormone release inhibiting factor | Inhibits α-MSH release inhibitors. Also increase dopamine levels. | |
| HB0407 | Memantine hydrochloride | Non-competitive NMDA receptor antagonist | >98% |
| HB1623 | Metergoline | 5-HT1/5-HT2 antagonist. Shows affinity for 5-HT6 and 5-HT7 | |
| HB1822 | L-(-)-α-Methyldopa | L-aromatic amino acid decarboxylase inhibitor | |
| HB4135 | MG132 | Potent, cell-permeable proteasome inhibitor. Calpain inhibitor. | >99% |
| HB2783 | Mifepristone | Potent glucocorticoid and progesterone receptor antagonist | >99% |
| HB1759 | Milnacipran hydrochloride | 5-HT and norepinephrine re-uptake inhibitor (SNRI) | >99% |
| HB0412 | Miltefosine | Akt inhibitor | >98% |
| HB3976 | MK-571 sodium salt | Selective leukotriene LTD4 receptor antagonist. Potent MRP1 inhibitor. | >97% |
| HB0004 | (+)-MK 801 maleate | Potent, selective, non-competitive NMDA receptor antagonist | >98% |
| HB0414 | ML 289 | Selective mGlu3 negative allosteric modulator | >98% |
| HB0415 | ML-7 hydrochloride | Selective MLCK inhibitor | >99% |
| HB0092 | MMPX | Selective calmodulin-dependent PDE-1 inhibitor | >98% |
| HB0423 | MNI-caged-L-Glutamate | Caged glutamate that rapidly and efficiently releases glutamate when photolysed | >98% |
| HB1791 | Moclobemide | Reversible MAO-A inhibitor | >99% |
| HB0860 | Modafinil | Dopamine transporter (DAT) inhibitor | >98% |
| HB0260 | D-NG-Monomethylarginine (D-NMMA) | Inactive enantiomer of L-NMMA | >98% |
| HB0426 | MPEP hydrochloride | Potent, selective mGluR5antagonist / mGluR4 positive allosteric modulator | >98% |
| HB0428 | mpV(pic) | Phosphotyrosine phosphatase inhibitor | |
| HB1966 | MRS 2578 | Potent, selective P2Y6 receptor antagonist | >95% |
| HB3983 | MS-275 | HDAC 1 inhibitor | >98% |
| HB1450 | MS 436 | Potent, selective BRD4 bromodomain inhibitor | >98% |
| HB0431 | MTEP hydrochloride | Potent, highly selective, non-competitive mGluR5antagonist | >98% |
| HB3987 | Mycophenolic acid | Inosine monophosphatase dehydrogenase inhibitor | >98% |
| HB2451 | Naloxone hydrochloride | Competitive opioid receptor antagonist | >99% |
| HB2452 | Naltrexone hydrochloride | Competitive opioid receptor antagonist | >99% |
| HB1352 | L-NAME | Non-selective NOS inhibitor | >98% |
| HB0066 | 1-Naphthyl PP1 | Potent, selective src family kinase inhibitor | >99% |
| HB0439 | N-Arachidonylglycine (NAGly) | Endogenous GLYT2 inhibitor / Cav3.1 / 3.2 / 3.3 current inhibitor | |
| HB0440 | N-Arachidonyl-L-alanine | GLYT2 / GLYT2(EL2) inhibitor | >98% |
| HB0441 | Naspm trihydrochloride | Selective GluA2- lacking, Ca2+ permeable AMPA / kainate receptor antagonist | >97% |
| HB0442 | NBQX | Potent, selective, competitive AMPA receptor antagonist | >98% |
| HB0443 | NBQX disodium salt | Potent, selective, competitive AMPA receptor antagonist. Disodium salt. | >98% |
| HB3992 | Nebularine | Naturally occuring nucleoside. DNA, RNA and protein synthesis inhibitor. | >98% |
| HB3994 | Necrostatin-5 | Necroptosis inhibitor. Indirect RIP1 kinase inhibitor. | >98% |
| HB3995 | Necrostatin-7 | Necroptosis inhibitor. Shows no action at RIP1 kinase. | >98% |
| HB3996 | Neoxaline | G2/M phase cell cycle inhibitor | >97% |
| HB1961 | NF 449 | Potent, selective, competitive P2X receptor antagonist | |
| HB3719 | 22-NHC (inactive isomer) | Inactive control compound for hedgehog signaling inhibitor 22-NHC | >98% |
| HB1435 | Niclosamide | STAT3 signaling pathway inhibitor. Antineoplastic against AML stem cells | >99% |
| HB1228 | Nifedipine | L-type Ca2+ channel blocker | >98% |
| HB1353 | L-NMMA | Competitive, selective NOS inhibitor | |
| HB3999 | Nocodazole | Mitosis inhibitor. Widely used as a cell cycle synchronizing agent. | >98% |
| HB0466 | Nω-Propyl-L-arginine hydrochloride | Potent, selective nNOS inhibitor | >98% |
| HB0457 | NPC-15437 dihydrochloride | Competitive, selective PKC inhibitor | |
| HB1430 | NSC 33994 | Potent, selective JAK2 inhibitor | >98% |
| HB1392 | NSC 3852 | Non-selective HDAC inhibitor | |
| HB4001 | NSC697923 | Selective Ub-conjugating enzyme (E2) complex Ubc13-Uev1A inhibitor | >98% |
| HB1436 | NSC 74859 | Selective STAT3 inhibitor | >98% |
| HB4002 | NU6102 | Potent CDK1 and CDK2 inhibitor | >98% |